NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Fog Pharmaceuticals

Fog Pharmaceuticals

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://parabilismed.com/

Last Round

Private Placement

Jun 12, 2026

Est. Valuation

$2.3B

Total Funding Raised

$812M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Parabilis Medicines is a biopharmaceutical company that develops Helicon™ peptide therapeutics designed to target and neutralize historically undruggable intracellular cancer-causing proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discoveryprecision medicinebiotechAI drug discoveryundruggable targetsHelicon therapeuticsin silico drug designphysics-based modelingcell-permeable peptidesHEARTsHelicon-Enabled ARTsalpha-radioligand therapeuticstherapeutic co-developmentsmall molecule alternativescomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fog Pharmaceuticals Comparables

Compare Fog Pharmaceuticals with similar companies based on industry and business-model similarity.

Fog Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Relay Therapeutics
78%
PeptiDream Inc.
76%
Recursion Pharmaceuticals
76%

Fog Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private PlacementJun 12, 2026
IPOJun 10, 2026
Series FJan 8, 2026
Series EMar 1, 2024
Series DNov 21, 2022
Series C
Mar 1, 2021

Fog Pharmaceuticals Investors

Notable investors and investment history

Fog Pharmaceuticals investors
InvestorRounds
Soleus CapitalSeries F
Deerfield ManagementSeries C, Series A, Seed, Series B, Series D
Evercore ISIIPO
Janus Henderson GroupSeries F
Horizons VenturesSeries B
SymBiosis Capital ManagementSeries E
Boyu CapitalSeed, Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 10, 2026

    $771M IPO round led by Guggenheim Securities.

  • Jan 8, 2026

    $305M round led by Fidelity, Janus Henderson, and RA Capital.

Fog Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Fog Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Fog Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Year Founded2015
Last FundingJun 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.